Fusion genes identified in B-ALL patients. Data are presented for 99 patients with B-ALL on whom we performed RNA-seq. Each column represents a single patient. Patients were classified as “Defined” if they fell into a WHO-established subtype (n = 67) or “Undefined” (n = 32), according to the key. NCI risk classification, MRD at the end of induction, outcome data, where event indicates death or relapse, and IKZF1 status, determined by microarray or RQ-PCR assay, are shown for each patient and colored according to the key. Rearrangements are identified by standard clinical test (standard) including G-banding analysis (karyotype) or FISH analysis and are shown in green. The RNA-seq row denotes fusions identified by RNA-seq using JAFFA and are shown in blue. The gray and blue bar represents a sample in which an IGH-CRLF2 rearrangement, identified by karyotype, was missed by RNA-seq but a PAX5 rearrangement was identified by RNA-seq. Nonstandard rearrangements identified are colored according to the key. *IGH-CRLF2 rearrangement identified by karyotype and not identified by RNA-seq.